Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab

Samsung Biologics and Checkpoint Therapeutics announced the expansion of a long-term manufacturing partnership for Checkpoint's anti-PD-L1 antibody, cosibelimab. Building upon an existing contract manufacturing agreement entered into in 2017, Samsung Biologics will provide additional commercial-scale drug substance manufacturing for Checkpoint. Under the new agreement, Samsung Biologics will commence manufacturing in 2021 in Plant 1.

James F. Oliviero, President and Chief Executive Officer of Checkpoint Commented "We look forward to continuing our manufacturing partnership with Samsung Biologics for our lead product candidate, cosibelimab, currently in a pivotal clinical trial for metastatic cutaneous squamous cell carcinoma. Checkpoint is on track to report full topline results from the pivotal trial in mid-2021, This agreement provides Checkpoint access to a top-tier manufacturing site for the long-term commercial supply of cosibelimab after potential regulatory approvals worldwide."

Dr. Tae Han Kim, CEO of Samsung Biologics Commented "We are extremely proud of this extended partnership with Checkpoint to support our client and make an impact by helping broader patient populations in need, As a reliable contract development and manufacturing organization ("CDMO") service provider, Samsung Biologics offers the highest quality manufacturing for Checkpoint to assist in its endeavor to bring innovative treatments for patients all around the globe."

Related Posts

Subscribe Our Newsletter